[{"orgOrder":0,"company":"Allegheny Singer Research Institute","sponsor":"CTM Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Allegheny Singer Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegheny Singer Research Institute \/ CTM Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Allegheny Singer Research Institute \/ CTM Biomedical"}]

Find Clinical Drug Pipeline Developments & Deals for Thalomid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Allegheny Singer Research Institute

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Allegheny Singer Research Institute

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Celgene is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rotator Cuff Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Thalidomide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : CTM Biomedical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank